Many factors such as immune contexture and tumor microenvironment, expression of PD-L1 and LAG3, TMB, genetic and epigenetic alterations, antigen-presenting molecules (MHC, HLA) and microbiota may all contribute to the resistance to immunotherapy (102). This evidence concerns the gene HLA-C and neoplasm.